Cappella Inc.
This article was originally published in Start Up
Executive Summary
Of the more than one million percutaneous coronary interventions performed in the US last year, approximately 20% of cases involved bifurcations. Even with the advent of drug-eluting stents (DES) as well as dedicated bifurcation stenting systems and creative stenting techniques, lesion histology, patient anatomy, and equipment limitations have frequently led to suboptimal results. Cappella was founded with the goal of improving outcomes in patients with bifurcated lesions.